J. Stern & Co. LLP Has $45.21 Million Holdings in Abbott Laboratories $ABT

Key Points

• J. Stern & Co. LLP increased its holdings in Abbott Laboratories by 8.0% to approximately $45.21 million, making Abbott their 13th largest investment.
• Several hedge funds have also shown interest in Abbott, with 75.18% of the stock now owned by institutional investors and hedge funds, indicating strong market confidence.
• Abbott Laboratories reported a quarterly earnings per share of $1.26, in line with analyst expectations, and a revenue increase of 7.4% year-over-year.

J. Stern & Co. LLP lifted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 8.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 340,786 shares of the healthcare product maker's stock after acquiring an additional 25,353 shares during the period. Abbott Laboratories makes up approximately 4.3% of J. Stern & Co. LLP's holdings, making the stock its 13th biggest holding. J. Stern & Co. LLP's holdings in Abbott Laboratories were worth $45,205,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Kelly Financial Services LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth approximately $216,000. Voleon Capital Management LP acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $273,000. Bank Pictet & Cie Europe AG raised its holdings in Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after buying an additional 2,774 shares during the period. Edge Financial Advisors LLC grew its stake in shares of Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after acquiring an additional 81 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Abbott Laboratories by 6.5% during the 4th quarter. Ameriprise Financial Inc. now owns 12,865,656 shares of the healthcare product maker's stock worth $1,451,032,000 after acquiring an additional 781,264 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. Mizuho raised their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Leerink Partners assumed coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Finally, BTIG Research decreased their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $144.47.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.46% of the company's stock.

Abbott Laboratories Trading Down 0.4%

ABT stock opened at $132.0240 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The company has a fifty day moving average price of $131.04 and a two-hundred day moving average price of $131.33. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The stock has a market cap of $229.78 billion, a price-to-earnings ratio of 16.54, a price-to-earnings-growth ratio of 2.51 and a beta of 0.70.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, July 15th. Abbott Laboratories's payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.